Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
80.4M
-
Number of holders
-
281
-
Total 13F shares, excl. options
-
79.9M
-
Shares change
-
+1.12M
-
Total reported value, excl. options
-
$3.9B
-
Value change
-
+$46.6M
-
Put/Call ratio
-
0.59
-
Number of buys
-
166
-
Number of sells
-
-117
-
Price
-
$48.84
Significant Holders of PTC THERAPEUTICS, INC. - Common Stock (PTCT) as of Q2 2025
330 filings reported holding PTCT - PTC THERAPEUTICS, INC. - Common Stock as of Q2 2025.
PTC THERAPEUTICS, INC. - Common Stock (PTCT) has 281 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 79.9M shares
of 80.4M outstanding shares and own 99.35% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (8.85M shares), RTW INVESTMENTS, LP (7.75M shares), BlackRock, Inc. (7.48M shares), ARMISTICE CAPITAL, LLC (4.74M shares), WELLINGTON MANAGEMENT GROUP LLP (4.69M shares), JANUS HENDERSON GROUP PLC (3.18M shares), STATE STREET CORP (3M shares), TORONTO DOMINION BANK (2.45M shares), D. E. Shaw & Co., Inc. (2.44M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.93M shares).
This table shows the top 281 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.